John Hohneker ’81 is President of Research and Development at FORMA Therapeutics Inc., a privately held biopharmaceutical company focused on finding new medicines for people with cancer and other serious diseases. He also a member of the Board of Directors for Dimension Therapeutics Inc, a publicly traded gene therapy company.
Over the past 25 years, he has been committed to drug discovery and development, including 14 years at Novartis – where he was most recently responsible for the global development of the immunology, rheumatology, and dermatology product pipelines. He has played a key role in the development, approval, and/or commercialization of 14 new drugs.
Hohneker, a medical oncologist, has served on the research committee of the American Society of Clinical Oncology, as well as the Institute of Medicine’s Cancer Policy Forum. Today, his contributions to the scientific community appear in numerous publications.
A member of Skeptical Chemists and Phi Beta Kappa at Gettysburg, Hohneker graduated with a BA in Chemistry. He received his MD from the University of Medicine and Dentistry of New Jersey, Rutgers Medical School (Robert Wood Johnson Medical School), in 1985.
Inga Holl Musselman ’82 is the Interim Provost and Professor of Chemistry at The University of Texas at Dallas. She has received numerous research grants and has contributed to a host of scientific publications, all while handling a progressively larger administrative workload. She also has six patents/patent applications for her exceptional work in the lab.
Following her graduation from Gettysburg, Musselman earned her PhD in Chemistry from the University of North Carolina at Chapel Hill in 1988, and completed her postdoctoral research in Materials Science from North Carolina State University in 1991.
Musselman was a member of the College’s field hockey team and Skeptical Chemists. She graduated in 1982 with a BA in Chemistry and received departmental honors for her academic achievements.